BioMarin Reviews Status of Exon 51 Composition of Matter and Method of Use Patent Interference Cases against Sarepta Therapeutics
المصدر:
Nasdaq GlobeNewswire
/
21 سبتمبر 2016 08:54:15 America/New_York
N/A
شارك على،